Benzinga (Wed, 11-Feb 9:00 AM ET)
AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
TipRanks (Tue, 10-Feb 11:30 AM ET)
96 of 123 S&P 500 companies post EPS growth in latest earnings week: Earnings scorecard
Seeking Alpha News (Sat, 7-Feb 4:05 PM ET)
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week
Seeking Alpha News (Sat, 7-Feb 11:30 AM ET)
TipRanks (Fri, 6-Feb 8:25 AM ET)
AbbVie (ABBV) Receives a Buy from Guggenheim
TipRanks (Fri, 6-Feb 7:47 AM ET)
AbbVie Delivers Record $61.16 Billion in 2025 Revenues, Signals Strong Growth for 2026
Market Chameleon (Wed, 4-Feb 3:27 AM ET)
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
PRNewswire (Wed, 4-Feb 7:48 AM ET)
PRNewswire (Tue, 3-Feb 8:50 AM ET)
PRNewswire (Tue, 3-Feb 8:00 AM ET)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Abbvie trades on the NYSE stock market under the symbol ABBV.
As of February 11, 2026, ABBV stock price climbed to $222.88 with 2,076,623 million shares trading.
ABBV has a beta of 0.32, meaning it tends to be less sensitive to market movements. ABBV has a correlation of 0.05 to the broad based SPY ETF.
ABBV has a market cap of $393.70 billion. This is considered a Mega Cap stock.
Last quarter Abbvie reported $17 billion in Revenue and $2.71 earnings per share. This beat revenue expectation by $225 million and exceeded earnings estimates by $.05.
In the last 3 years, ABBV traded as high as $244.81 and as low as $130.96.
The top ETF exchange traded funds that ABBV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ABBV has outperformed the market in the last year with a price return of +20.6% while the SPY ETF gained +15.3%. ABBV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2.7% and -0.5%, respectively, while the SPY returned +1.6% and -0.7%, respectively.
ABBV support price is $218.85 and resistance is $226.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABBV shares will trade within this expected range on the day.